Two patients with MASH share their paths to diagnosis, including the challenges they faced and what it took to find answers.

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

As the definitive trial comparing Wegovy to Mounjaro is released, experts stress the need for patients to be given the very ...